Myriad Genetics Appoints Raj Jampa As CTO
(RTTNews) - Myriad Genetics, Inc., (MYGN), a molecular diagnostic testing and precision medicine company, Tuesday announced that it has appointed Raj Jampa as its chief technology officer, effective June 1.
Before joining the diagnostic and precision medicine company, Jampa held senior technology leadership roles at Agilent Technologies, Exact Sciences and Genomic Health.
In pre-market activity, MYC+GN shares were trading at $4.19, down 2.10% on the Nasdaq.
Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.